Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Huber

Showing results (541-550 of 642) with videos related to

Pageof 65
Sort By:
Internal and Emergency Medicine|September 21, 2020
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation RegistryGiulia Renda, Ladislav Pecen, Giuseppe Patti, et al.
European Heart Journal|April 22, 2015
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary interventionDániel Aradi, Ajay Kirtane, Laurent Bonello, et al.
Thrombosis and Haemostasis|January 10, 2014
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic SubstudyRobert F Storey, Jayaprakash Kotha, Susan S Smyth, et al.
The New England Journal of Medicine|March 12, 2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarctionPaul W Armstrong, Anthony H Gershlick, Patrick Goldstein, et al.
American Heart Journal|February 9, 2018
Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC studyAkshay Bagai, Shaun G Goodman, Warren J Cantor, et al.
European Heart Journal. Acute Cardiovascular Care|August 26, 2017
Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC TrialEnrico Fabris, Arnoud van 't Hof, Christian W Hamm, et al.
Lancet (London, England)|September 1, 2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trialDirk Sibbing, Dániel Aradi, Claudius Jacobshagen, et al.
Circulation|December 28, 2018
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular RiskMichelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, et al.
American Heart Journal|November 26, 2013
Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percutaneous coronary interventionPhilippe Gabriel Steg, Arnoud van 't Hof, Peter Clemmensen, et al.
Frontiers in Cardiovascular Medicine|April 10, 2023
Data processing pipeline for cardiogenic shock prediction using machine learningNikola Jajcay, Branislav Bezak, Amitai Segev, et al.
Pageof 65

Showing results (541-550 of 642) with videos related to

Sort By:
Pageof 65
Internal and Emergency Medicine|September 21, 2020
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation RegistryGiulia Renda, Ladislav Pecen, Giuseppe Patti, et al.
European Heart Journal|April 22, 2015
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary interventionDániel Aradi, Ajay Kirtane, Laurent Bonello, et al.
Thrombosis and Haemostasis|January 10, 2014
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic SubstudyRobert F Storey, Jayaprakash Kotha, Susan S Smyth, et al.
The New England Journal of Medicine|March 12, 2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarctionPaul W Armstrong, Anthony H Gershlick, Patrick Goldstein, et al.
American Heart Journal|February 9, 2018
Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC studyAkshay Bagai, Shaun G Goodman, Warren J Cantor, et al.
European Heart Journal. Acute Cardiovascular Care|August 26, 2017
Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC TrialEnrico Fabris, Arnoud van 't Hof, Christian W Hamm, et al.
Lancet (London, England)|September 1, 2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trialDirk Sibbing, Dániel Aradi, Claudius Jacobshagen, et al.
Circulation|December 28, 2018
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular RiskMichelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, et al.
American Heart Journal|November 26, 2013
Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percutaneous coronary interventionPhilippe Gabriel Steg, Arnoud van 't Hof, Peter Clemmensen, et al.
Frontiers in Cardiovascular Medicine|April 10, 2023
Data processing pipeline for cardiogenic shock prediction using machine learningNikola Jajcay, Branislav Bezak, Amitai Segev, et al.
Pageof 65